AliveX Biotech Secures Spot in 2024 Qipu Seed List Top 10 with AI-Driven Multi-Omics Drug Discovery Platform
AliveX Biotech
Precision Medicine Solution Provider
In the selection of the "2024 Qipu Seed List",AliveX Biotech Honored on "Top 10 Health Digital Innovation Q-Pod Seed List" with Its "AI + Multi-Omics Biomedical R&D Solution", becoming the industry focus with its excellent technical strength and innovation capabilities.
This honor marks AliveX Biotech's卓越地位 in technological innovation and industry transformation, showcasing its leading technology and差异化创新能力 in the health digital intelligence field.
The 5th "Qipu Award" Ceremony
On November 24, the 2024 China Health Industry Innovation Summit and the 5th "Qipu Award" Ceremony successfully concluded at the Shanghai Hongqiao Conference Center.
The award ceremony was filled with a lively atmosphere, attended by a large array of distinguished guests. In addition to leaders such as Hu Hongyi, Deputy Director of the Shanghai Municipal Health Commission, and Ke Xiaolin, Deputy District Chief of Minhang District in Shanghai, authoritative experts from the medical and health industry, academia, members of the judging panel, and business leaders were also present. Nearly twenty influential figures from the government, academia, and the industry jointly witnessed this significant event, showcasing the important status of the CHIP Award as a benchmark for innovation and development in China's healthcare industry.
Looking Ahead: Innovation Leads the New Development of the Health Industry
AliveX Biotech stands out in the health digital intelligence track with its "AI + multi-omics biopharmaceutical R&D solutions," showcasing its differentiated innovation capabilities in areas of unmet clinical needs. This honor not only affirms AliveX Biotech's technological leadership but also highlights its industry position in driving the transformation of biopharmaceutical R&D.
Top 10 Project Representatives of the 2024 Health Digital Intelligence Track Chip Seed Award (Ms. Wenwen, Fourth from the Left)
In the future, AliveX Biotech will further deepen the integration of AI and multi-omics technologies, committing to technological innovation and the transformation of achievements, creating more value for society, and leading new directions in the development of the health industry.
About AliveX Biotech
AliveX Biotech is a leading AI + multi-omics technology platform company in China, possessing an end-to-end dry and wet lab closed-loop multi-omics experimental platform as well as an AI biocomputing platform. This includes high-quality bioanalytical technologies such as spatiotemporal single-cell omics, targeted proteomics, metabolomics/lipidomics, along with computational technologies like multi-omics integrated analysis, AI modeling, knowledge graphs, and disease pharmacological mechanism modeling to efficiently empower research and development. AliveX Biotech has an internationally renowned interdisciplinary team of academician professors and industry experts, providing customized scientific research solutions for research institutions and pharmaceutical partners, including studies on disease and drug mechanisms, discovery and evaluation of biomarkers and targets, patient stratification, multimodal AI prediction, optimization of clinical trial protocols, and precision medicine strategies. AliveX Biotech has served over a hundred clinical and research institutes as well as international large pharmaceutical companies. The company holds dozens of core technology independent intellectual property rights and has obtained National High-Tech Enterprise Certification, CAP certification from the American Association of Pathologists, and ISO9001 certification.
